Good afternoon, and welcome to the NVE Corporation Conference Call for the quarter ended September 30, 2025. The I'm Dan Baker, NVE's President and CEO. I'm joined by Daniel Nelson, our Principal ...
Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback